60% Of Vetr Crowd Bullish On Valeant Despite Recent Downgrade

Shares of

gained more than 20 percent over the past month but are still lower by more than 50 percent over the past six months. Related Link:

The Vetr crowd appears turned slightly less bullish on Valeant Pharmaceuticals' stock and downgraded its rating to 4-stars out of a possible 5-stars. In fact, Valeant's stock has fallen to $108.76 since the previous rating of 4.5-stars was issued just four days ago. Despite the fact that 60 percent of the crowd's ratings are bullish, the crowd-sourced price target of $121.12 implies a potential upside of more than 12 percent.